This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Pegylated Interferon and Ribavirin-Induced Depression in Chronic Hepatitis C: Role of Personality

Pere Castellvi, Ricard Navinés, Fernando Gutierrez, Dolors Jiménez, Carme Márquez, Susana Subirí , Ricard Solí , and Rocí­o Martí­n-Santos

Published: June 17, 2009

Article Abstract

Objective: Pegylated interferon (PegIFN) and ribavirin (RBV) treatment for the hepatitis C virus (HCV) infection can induce depressive episodes. Personality traits have been associated with mood disorders. The aim of this study was to evaluate the personality profile as a risk factor for induced depression by PegIFN and RBV treatment in patients with HCV.

Method: In a prospective cohort study, 204 consecutive HCV outpatients who received PegIFN and RBV were assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders and the Temperament and Character Inventory-Revised (TCI-R). Moreover, the Patient Health Questionnaire and the Hospital Anxiety and Depression Scale were administered at baseline and at 4, 12, 24, and/or 48 weeks of treatment. Patients were recruited between September 2003 and December 2006.

Results: One hundred eighteen patients (57.8%) were men. The mean (SD) age was 44.39 (10.4) years. The incidence of induced depression during the 48 weeks of antiviral treatment was 73 (42%). Low self-directedness dimension (HR = 0.63, 95% CI = 0.446 to 0.890, p =.009), baseline subclinical depression levels (HR = 1.113, 95% CI = 1.023 to 1.22, p =.013), and history of mood disorders (HR = 0.372, 95% CI = 0.220 to 0.629, p

Conclusion: Low self-directedness, depressive symptoms at baseline, and history of previous mood disorders may predict induced depression by PegIFN and RBV in euthymic HCV patients.

Volume: 70

Quick Links: Hepatitis , Medical

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF